<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960594</url>
  </required_header>
  <id_info>
    <org_study_id>TRT-001</org_study_id>
    <nct_id>NCT02960594</nct_id>
    <nct_alias>NCT02327468</nct_alias>
  </id_info>
  <brief_title>hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse</brief_title>
  <acronym>TRT-001</acronym>
  <official_title>A Study of hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inovio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Inovio Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity
      of INO-1400 alone or in combination with INO-9012, delivered by electroporation in subjects
      with high-risk solid tumor cancer with no evidence of disease after surgery and standard
      therapy. Subjects will be enrolled into one of six treatment arms. Subjects will be assessed
      according to standard of care. Restaging and imaging studies will be performed to assess
      disease relapse per NCCN guidelines. RECIST will be used to validate the findings in cases of
      relapse.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events graded in accordance with &quot;Common Terminology Criteria for Adverse Events (CTCAE)&quot;, NCI version 4.03</measure>
    <time_frame>Up to 2 years from first study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Injection site reactions including, but not necessarily limited to, local skin erythema, induration, pain and tenderness at administration site</measure>
    <time_frame>Up to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in safety laboratory parameters</measure>
    <time_frame>Up to 2 years from first study treatment</time_frame>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>ColoRectal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>HepatoCellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg INO-1401 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg INO-1401 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-1400</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_label>Arm 6</arm_group_label>
    <other_name>hTERT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-9012</intervention_name>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_label>Arm 9</arm_group_label>
    <arm_group_label>Arm 10</arm_group_label>
    <other_name>IL-12</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-1401</intervention_name>
    <arm_group_label>Arm 7</arm_group_label>
    <arm_group_label>Arm 8</arm_group_label>
    <arm_group_label>Arm 9</arm_group_label>
    <arm_group_label>Arm 10</arm_group_label>
    <other_name>SynCon TERT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Signed and dated written IRB approved informed consent;

          -  2. Males or females aged â‰¥18 years;

          -  3. Subjects with breast, lung or pancreatic carcinoma who are at high risk of relapse
             post definitive therapy at least 4 and no more than 24 weeks from completion of
             definitive therapy at the time of signing informed consent as described below for each
             indication:

               -  Breast carcinoma:

               -  Lung carcinoma:

               -  Pancreatic carcinoma:

               -  Head and neck squamous cell carcinoma:

               -  Ovarian cancer:

               -  Colorectal cancer

               -  Gastric and esophageal cancer

               -  Hepatocellular carcinoma

        Exclusion Criteria:

          -  1. Previous treatment wth any TERT or IL-12 containing therapy, or any other DNA
             immunotherapy;

          -  2. Any concurrent condition requiring the continued or anticipated use of systemic
             steroids (excluding non-systemic inhaled, topical skin and/or eye drop-containing
             corticosteroids) or immunosuppressive therapy (excludes low dose methotrexate). All
             other systemic corticosteroids must be discontinued at least 4 weeks prior to first
             Study Treatment;

          -  3. Administration of any vaccine within 4 weeks of the first study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Vonderheide, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Autumn McRee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University Hospitial</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony Shields, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karmanos Cancer Center (Wayne State University)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathan Bahary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ashish Chintakuntlawar, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic (Rochester, MN)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karmanos Cancer Center (Wayne State University)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospitial</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.inovio.com</url>
    <description>Sponsor's Website</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Human Telomerase Reverse Transcriptase (hTERT)</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Pancreatic Neoplasms</keyword>
  <keyword>High Risk of Relapse</keyword>
  <keyword>Post Definitive Surgery</keyword>
  <keyword>Post Adjuvant Therapy</keyword>
  <keyword>No Evidence of Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-12</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

